Gate2Brain obtains €700,000 in funding from the CDTI Multicountry program to advance a therapy against pediatric brain tumors in collaboration with India
Gate2Brain, a spin-off of the University of Barcelona, IRB Barcelona, and San Juan de Dios Hospital, has secured €700,000 in funding from the Center for Industrial Technological Development (CDTI Innovación) through the Multipaís 2024 program. This financial support represents a significant milestone for Gate2Brain and will boost the development of its innovative approach to drug delivery for the treatment of central nervous system (CNS) diseases.
The funding is part of Spain’s Recovery, Transformation, and Resilience Plan, within the framework of the PERTE (Cutting-Edge Health) initiative, which promotes the development of pioneering healthcare technologies with the potential to transform patient care. The project also has support from the Ministry of Science and Innovation and the European Union (NextGenerationEU), reflecting the strategic importance of this research.
An international collaboration for a high-impact therapy
Gate2Brain is leading an international initiative in which Spain and India are working together to accelerate the clinical development of G2B-002. This therapy is specifically designed for the treatment of high-grade pediatric brain tumors and has already demonstrated:
- Effective penetration of the blood-brain barrier using Gate2Brain’s unique shuttle peptide technology.
- Promising anticancer activity observed in preclinical models.
- Good tolerance observed in initial studies, laying the groundwork for further clinical validation.
This funding will allow the spin-off to complete the regulatory preclinical development of G2B-002 and advance toward a clinical trial in pediatric patients with diffuse midline glioma (DMG) by the end of 2027.